We are live on ! Find out more
INBX icon

Inhibrx
INBX

101 hedge funds and large institutions have $172M invested in Inhibrx in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more call options, than puts

Call options by funds: $1.28M | Put options by funds: $418K

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

23% more capital invested

Capital invested by funds: $139M → $172M (+$32.6M)

15.66% more ownership

Funds ownership: 61.45% → 77.11% (+16%)

5% more funds holding

Funds holding: 96 → 101 (+5)

7% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 29

Holders
101
Holders Change
+5
Holders Change %
+5.21%
% of All Funds
1.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
17
Increased
31
Reduced
29
Closed
11
Calls
$1.28M
Puts
$418K
Net Calls
+$860K
Net Calls Change
-$1.42M

Top Buyers

Rank Fund Capital Flow
1
HighTower Advisors
HighTower Advisors
Illinois
+$10M
2
BlackRock
BlackRock
New York
+$1.75M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.36M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.18M
5
Goldman Sachs
Goldman Sachs
New York
+$544K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$3.04M
2
CL
CSS LLC
Illinois
-$631K
3
Marshall Wace
Marshall Wace
United Kingdom
-$564K
4
Millennium Management
Millennium Management
New York
-$472K
5
Russell Investments Group
Russell Investments Group
United Kingdom
-$453K
Name Holding Trade Value Shares
Change 		Change in
Stake
CIEC
26
Crédit Industriel et Commercial
France
$989K +$978K +64,217 New
Goldman Sachs
27
Goldman Sachs
New York
$885K +$544K +35,685 +164%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$837K -$453K -29,766 -35%
Marshall Wace
29
Marshall Wace
United Kingdom
$825K -$564K -37,061 -41%
CL
30
CSS LLC
Illinois
$796K -$631K -41,413 -44%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$792K +$392K +25,712 +100%
RC
32
Rangeley Capital
Connecticut
$761K +$752K +49,401 New
IC
33
Ikarian Capital
Texas
$649K -$15 -1 -0%
Morgan Stanley
34
Morgan Stanley
New York
$612K -$3.04M -199,525 -83%
Fidelity Investments
35
Fidelity Investments
Massachusetts
$597K +$49.4K +3,242 +9%
YCM
36
Yakira Capital Management
Connecticut
$557K – – –
M
37
Murchinson
Ontario, Canada
$520K – – –
GCP
38
GSA Capital Partners
United Kingdom
$520K -$118K -7,778 -19%
Charles Schwab
39
Charles Schwab
California
$503K – – –
BC
40
Birchview Capital
Vermont
$494K – – –
LNWWM
41
Laird Norton Wetherby Wealth Management
California
$472K -$30.9K -2,026 -6%
BFM
42
Boothbay Fund Management
New York
$435K -$15 -1 -0%
APCM
43
Arbiter Partners Capital Management
New York
$433K – – –
N
44
Nuveen
North Carolina
$385K -$241K -15,850 -39%
MWA
45
Meridian Wealth Advisors
Texas
$385K +$381K +25,000 New
EWM
46
Empirical Wealth Management
Washington
$348K +$344K +22,584 New
JC
47
JBF Capital
Colorado
$323K – – –
Corient Private Wealth
48
Corient Private Wealth
Florida
$316K +$102K +6,667 +48%
Deutsche Bank
49
Deutsche Bank
Germany
$302K +$297K +19,487 +15,973%
Barclays
50
Barclays
United Kingdom
$290K +$42.4K +2,786 +17%
1
2
3 4 5

INBX Hedge Fund Activity: Q4 2024 in Review

101 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q4 2024, worth a combined $172M — up 23% from $139M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new INBX positions and 11 closed out — a net gain of 6 holders — while 31 added to existing stakes and 29 trimmed.

The largest buyer was HighTower Advisors, adding an estimated $10M. The largest seller was Morgan Stanley, cutting an estimated $3.04M.

  • 101 institutional investors held Inhibrx (INBX) as of Q4 2024, up from 96 in Q3 2024.
  • Funds reported $172M of Inhibrx stock for Q4 2024, up 23% quarter-over-quarter.
  • 17 funds opened new Inhibrx positions in Q4 2024 and 11 closed out, a net change of +6 holders.
  • The largest Inhibrx buyer in Q4 2024 was HighTower Advisors, an estimated $10M added.
  • The largest Inhibrx seller in Q4 2024 was Morgan Stanley, an estimated $3.04M sold.

Based on aggregated 13F filings for Q4 2024.